Entrepreneurship and spin-outs

The University actively supports researchers and academic staff in the creation of new ventures to bring new ideas and breakthrough innovations to market.

This support ranges from licensing IP, connecting with investors and partners and facilitating the creation of spinout companies.

If you are interested in finding out more about our pipeline of spinout companies and how you could get involved please contact:

University of Glasgow: Venture Portfolio

Aurum Biosciences develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need with an initial indication in stroke.

Brainwave delivers CNS testing services using transgenic fruit flies (Drosophila) to drug discovery companies. 

Caldan Therapeutics discovers novel therapeutics for metabolic diseases including Type 2 Diabetes and other indications.

Cara Therapeutics is involved in pre-clinical and clinical development of novel therapeutics to treat conditions associated with pain and inflammation.

‌‌Causeway Therapeutics Ltd has developed a microRNA therapy for the treatment of tendinopathy in human (TenoMiR) and equine (EquiMiR) patients.

Chemify will digitize chemistry and produce robotic solutions to run chemical code for drug discovery, chemical synthesis, and materials discovery

‌‌‌‌Clyde Biosciences provides new instrumentation and services for cell-based (including stem cell) testing for early detection of toxicity in drug discovery.

Clyde Hydrogen Systems has redefined the architecture for the next generation of green hydrogen production systems. The company has developed a new type of electrolysis that allows hydrogen and oxygen to be made in separate places and at different times and rates.

DeepMatter is a big data and analysis company which has built a platform focused on enabling reproducibility in chemistry. The company is at the forefront of the digitization of chemistry.

Dimensional Imaging develops 3D and 4D surface imaging software and services with applications in life sciences and entertainment industries.

Epeius pharma is a cell and gene therapy company developing next generation biological vehicles for delivery of therapeutic proteins into the central nervous system (CNS). The company's first target indication will be the debilitating neurological disorder, Rett Syndrome.

Intense uses propietary technology and processes to create diode laser products with unrivalled levels of power, brightness and reliability.

Keltic Pharma Therapeutics Ltd delivers translational programs for new medicines to cure and block transmission of the human malarial parasite and address unmet clinical needs in respiratory lung disease and neuropsychiatric disorders.

‌‌Kelvin Nanotechnology provides nanofabrication design and manufacturing services specialising in high resolution, electron beam lithography.

Lynkeos Technology develops imaging systems to inspect the contents of complex, shielded structures.

Multicorder offers fully integrated technology from silicon-design to mobile devices for fast, accurate, multiple biomarker measurement and diagnostic analysis.

NebuFlow unlocks delivery of the next generation of inhaled drugs for patients with widespread respiratory disorders, the main cause of death and disability worldwide.

Parkure has the sole mission of finding a cure for Parkinson’s disease by developing drugs that stop or delay the underlying process of neurodegeneration.

Portage Glasgow Ltd. (PGL) specialises in advancing drug candidates which disrupt medically important protein-protein interactions in cancer, age-related, senescent cell disorders and cardiovascular diseases.

Semiwise offers low power complementary metal-oxide-semiconductor (CMOS) technology that has the power to revolutionise the Internet of Things (IoT) and Artificial Intelligence (AI).

Solasta Bio is a nature-inspired insecticides discovery company focused on creating peptide-based insecticides that meet the global need for effective, new insect control products that are friendly to the environment and preserve beneficial insects such as bees.

 

Vector Photonics produces PCSEL (Photonic Crystal Surface Emitting Laser), semiconductor lasers – the most significant innovation in laser design and manufacture for 30 years.

Acquired companies

A number of our spinout companies and technologies have been acquired, recognising the growth potential of the companies and the impact of their technologies and services.

  • Kelvin Connect, a spin-out which specialised in mobile data capture systems - acquired by the UK emergency services’ communications provider Airwave Solutions Limited.
  • Gold Standard Simulations, a spin-out which specialised in advanced simulation tools for the semiconductor industry - acquired by Synopsys, a US-based chip design software company specialising in electronic design automation and semiconductor IP.
  • ReactivLab, a spin-out which developed animal health diagnostic technology - acquired by the Avacta Group which through its subsidiary, Avacta Animal Health, provided an established route to the veterinary market in the UK, EU and worldwide.
  • Kymata, an optical components company built on University of Glasgow technology - acquired by Gemfire, an optical components group.
  • Virttu Biologics, a spin-out which pioneered the development of oncolytic viruses for treating cancer - acquired by Sorrento Therapeutics, a clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases.